Trastuzumab resistance accompanies vasculogenic mimicry in HER2-positive breast cancer cells

被引：0
|
作者：
Shimoda, Masafumi [1 ]
Hori, Ami [1 ]
Noguchi, Shinzaburo [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Trastuzumab Use Modest in Patients With HER2-Positive Breast Cancer
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 339 - 339
  • [42] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    [J]. JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [43] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    [J]. CANCER RESEARCH, 2012, 72
  • [44] DNA methylation pattern to identify trastuzumab resistance in HER2-positive breast cancer models
    Palomeras, S.
    Diaz-Lagares, A.
    Setien, F.
    Ferreira, H. J.
    Hernandez, A.
    Vinas, G.
    Welm, A.
    Esteller, M.
    Puig, T.
    [J]. FEBS OPEN BIO, 2018, 8 : 314 - 314
  • [45] Association of Rac1 Expression with Trastuzumab Resistance In HER2-Positive Breast Cancer
    Varol, Umut
    Karaca, Burcak
    Patir, Pusem
    Sener, Alper
    Zekioglu, Osman
    Sanli, Ulus A.
    Uslu, Ruchan
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (04): : 219 - 226
  • [46] CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
    Xing, Fei
    Gao, Hongli
    Chen, Guanglei
    Sun, Lisha
    Sun, Jiayi
    Qiao, Xinbo
    Xue, Jinqi
    Liu, Caigang
    [J]. MOLECULAR CANCER, 2023, 22 (01)
  • [47] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [48] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    [J]. Current Oncology Reports, 2005, 7 (1) : 9 - 11
  • [49] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [50] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    [J]. BREAST CARE, 2021, 16 (03)
12345